Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 52

HOS-112183 · Präparat HOS-093615

The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2-blockers. Proton pump inhibitors Omeprazole 40 mg once daily Atazanavir (am): 2 hr after omeprazole Co-administration of (atazanavir 400 mg once daily Atazanavir AUC: ↓61% (↓65% ↓55%) REYATAZ with ritonavir and with ritonavir 100 mg once Atazanavir Cmax: ↓66% (↓62% ↓49%) proton pump inhibitors is not daily) Atazanavir Cmin: ↓65% (↓71% ↓59%) recommended. If the Omeprazole 20 mg once daily Atazanavir (am): 1 hr after omeprazole combination is judged (atazanavir 400 mg once daily Atazanavir AUC: ↓30% (↓43% ↓14%)* unavoidable, close clinical with ritonavir 100 mg once Atazanavir Cmax: ↓31% (↓42% ↓17%)* monitoring is recommended in daily) Atazanavir Cmin: ↓31% (↓46% ↓12%)* combination with an increase in the dose of REYATAZ to *When compared to atazanavir 300 mg 400 mg with 100 mg of once daily with ritonavir 100 mg once ritonavir; doses of proton daily. pump inhibitors comparable to omeprazole 20 mg should not The decrease in AUC, Cmax, and Cmin was be exceeded (see section 4.4). not mitigated when an increased dose of REYATAZ/ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours. Although not studied, similar results are expected with other proton pump inhibitors. This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir. The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors. Antacids Antacids and medicinal Reduced plasma concentrations of REYATAZ should be products containing buffers atazanavir may be the consequence of administered 2 hours before or increased gastric pH if antacids, including 1 hour after antacids or buffered medicinal products, are buffered medicinal products. administered with REYATAZ. ALPHA 1-ADRENORECEPTOR ANTAGONIST Alfuzosin Potential for increased alfuzosin Co-administration of alfuzosin concentrations which can result in with REYATAZ is hypotension. The mechanism of interaction contraindicated (see is CYP3A4 inhibition by REYATAZ section 4.3) and/or ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) ritonavir (HOS-084521) omeprazole (HOS-085912)